@article {7442,
	title = {Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients},
	journal = {Clinical Breast Cancer},
	volume = {16},
	year = {2016},
	note = {Cited By :1Export Date: 21 February 2017},
	month = {2016},
	pages = {291 - 298.e3},
	abstract = {Micro-Abstract We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy in women >65 years of age with early breast cancer. Elderly breast cancer patients derive clinical benefit comparable with that of younger patients, mainly at the cost of increased risk of hematological toxicity. {\textcopyright} 2015 Elsevier Inc.},
	keywords = {Clinical benefit, Competing risks analysis, Elderly patients, feasibility, Toxicity},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953775688\&doi=10.1016\%2fj.clbc.2015.12.001\&partnerID=40\&md5=8ade2bc4c35e7f13a2e1b9bb7ebd63d6},
	author = {Karavasilis, V. and Papadimitriou, C. and Gogas, H. and Kouvatseas, G. and Pentheroudakis, G. and Koutras, A. and Christodoulou, C. and Bafaloukos, D. and Samantas, E. and Pisanidis, N. and Papakostas, P. and Aravantinos, G. and Karanikiotis, C. and Kosmidis, P. and Pectasides, D. and Dimopoulos, M.-A. and Fountzilas, G.}
}
